A Life-Course Approach to Vaccination Can Drive Healthy Aging

As life spans increase and birth-rates decrease, the world’s population is aging. From 2000 to 2025, the over-60 demographic segment will double from 600 million to almost 1.2 billion. By 2050, it will nearly double again, surpassing two billion and accounting for an incredible 22% of the total global population. A society this “old” has never before existed, and it is a social, ethical, and economic imperative to keep older adults healthy and engaged. It is timely for the global public health community to re-align its thinking, policies and activities to this new demographic reality.

Organizations at national and global levels have begun to pursue initiatives to promote healthy aging, and these efforts are going to intensify in the coming years. Thus far, the progress has been admirable, with the World Health Organization, the United Nations, the Organisation for Economic Co-operation and Development, and others taking leadership roles. Yet, despite many promising developments, the potential of “life-course immunization,” which stresses the administration of vaccines throughout all stages of life – including for adults – to prevent disease and promote health, has been largely overlooked, especially among adults.

Benefits of Immunizations in Adults

As adults age, they increase their risk of contracting vaccine-preventable diseases like pneumococcal disease, herpes zoster (shingles), and influenza, among others. Immunization in the adult years – and throughout the life-course – enables adults to age with reduced risk to such vaccine-preventable diseases. Disease-free, older adults can remain active, healthy participants in society while curtailing increases in healthcare expenses and more fully engaging in economic life.

  • Professor of Global Ageing, University of Stirling, Scotland
  • Marjorie Coote Professor of Health Care for Older People,
    University of Sheffield
  • Founder, Sheffield Institute for Studies on Ageing (Winner
    of 2000 Queen’s Anniversary Prize)

The on-line geriatric assessment can be combined with different courses. The price of the courses ranges from 40 CHF to 1000 CHF depending on the level of desired training. The progressive model with the digital assessment tool which Geneva-based company calls Respond 4.0 is supposed to reduce health costs. The papi-boomer phenomenon, coupled with medical care sometimes too prompt to hospitalize, costs a lot to public authorities, who pay more than half of the hospital bill.

There is a wealth of evidence to suggest the health and economic benefits of influenza vaccination in adult populations.”

—GCoA Founder Michael Hodin

Similar research could and should also be done for other vaccine-preventable diseases – like herpes zoster (shingles), influenza, and hepatitis B – that older adults run increased risk of contracting. As we discuss below, this should be a major policy priority for policymakers and other stakeholders. Furthermore, with this data supporting the public health benefits of various adult immunizations, new vaccine innovations would be incentivized and, eventually, brought to market. This is also how childhood immunizations were developed, and the model of success should be brought to innovations in adult vaccines.

Remaining Obstacles

For all of the potential of life-course immunization programs, there do remain a number of barriers to implementation. Research by the Alliance for Health and the Future shows that, globally, the causes for the lack of uptake of life-course vaccination programs include complex vaccination schedules and inadequate physician knowledge. Patients, too, have limited awareness of the benefits of vaccinations for themselves and their families. There is a lack of vaccination recommendation alignment among national and global bodies, and this, in part, prevents patients from complying with recommendations.

Part of the problem is ideological.  Embedded attitudes about vaccines would shift with increased understanding of their value as adult immunization becomes a central part of public health thinking. Throughout the industrialized world, it is common for people to get vaccines before they travel abroad in order to prevent disease, but they do not consider the disease risks they face while at home. In the developing world, there is often lack of awareness and resources. As we have seen over the past few decades with childhood vaccinations, access is only part of the equation. The other part is raising awareness and understanding of how vaccines can improve health. The GAVI Alliance has done a tremendous job of creating an appreciation for children’s vaccines in the developing world. A similar level of attention needs to be placed on the critical value of adult vaccines as the global population ages.

Policy Priorities to Promote Life-Course Immunization

A life-course approach to immunization can only become a reality for people around the world with the dedication of and coordinated follow-through by policymakers. The most essential first steps are:

  • Increase awareness regarding the health benefits of life-course immunization among health professionals, as well as employers, employee groups, and unions; to be led by local and national governments, as well as global organizations like the World Health Organization;
  • Establish or enhance existing surveillance systems to determine the burden of vaccine-preventable diseases in adults; to be accomplished through partnership between national and global bodies;
  • Create institutional alignment on adult vaccination schedules among leading organizations like the World Health Organization, the Centers for Disease Control and Prevention, the European Union, the Pan American Health Organization, and others willing to participate
  • Integrate adult immunizations into Personal Medical Records and create an adult immunization registry; to be accomplished through partnership between private and public organizations;
  • Integrate adult vaccination in public and private payer access programs;
  • Embed adult vaccination in core preventive services for adults; advocacy to be led by both public and private organizations with a stake in cost containment and improved health outcomes;
  • Bring adult immunization into global public health as a matter of course in our 21st century; led, for example, by the World Health Organization and other multi-governmental organizations and NGOs.

Over the last couple of years, health and aging experts have made significant strides in rolling out plans for healthy aging initiatives. From President Obama’s pledge to end Alzheimer’s by 2025 to the United Nations’ historic summit on non-communicable diseases, national and global health leaders have pioneered new paths for healthy aging. Conspicuously missing from these efforts is a campaign for life-course immunization. Policymakers around the world should put life-course immunization at the top of their agenda in order to enable healthy aging and support social and economic success in the 21st century.

Source: Health Affairs

Latest Developments

We keep our members and partners in touch with the most recent updates and opinions in the worldwide dialogue on population longevity and related issues.

2024 AMR Preparedness Index Progress Report Highlights Urgent Need For Global Action Against Antimicrobial Resistance

Today, the Global Coalition on Aging (GCOA) and the Infectious Diseases Society of America (IDSA) launched the 2024 AMR Preparedness Index Progress Report. Released in the lead up to the United Nations General Assembly 2024 High-level Meeting on Antimicrobial Resistance (AMR) this September, the 2024 Progress Report assesses how the eleven largest global economies have advanced on calls to action laid out in the 2021 AMR Preparedness Index.

New Global Analysis Across Five Cities Shows Inequities in Adult Immunization Uptake, Signaling Need to Redesign Local and National Policy Interventions

GSK, in collaboration with the Global Coalition on Aging (GCOA), announced a new report from the IQVIA Institute for Human Data Science (IQVIA Institute). The report, funded by GSK, explores the role of social and structural determinants of health in adult vaccine access and uptake across five global cities with strong data about their aging populations: Bangkok, Thailand; Brussels, Belgium; Chicago, US; Manchester, United Kingdom; and New York City, US.

New Report From the Global Coalition on Aging Highlights the Connection Between Adult Immunization and Economic Health in Aging APEC Region

As leaders from across the Asia-Pacific Economic Cooperation (APEC) region convene in San Francisco over the next week, a new report from the Global Coalition on Aging (GCOA) points to investments in healthy aging as a growing economic imperative amid the region’s changing demographics. According to the new report, programs that keep populations healthy, active, and productive – like adult immunization – are increasingly becoming a prerequisite for economic stability and growth.

Menopause, the Silver Economy and Workplace Opportunities

As we recognise World Menopause Day, take a moment to consider the economic power, diverse expertise and skills, and incredible societal contributions of the estimated 1.1 billion post-menopausal women worldwide by 2025—a population on-par with China or India, and dwarfing any other country. Indeed, if we want to fuel the vibrant $15 trillion silver economy, societies, governments, and employers must empower older women in the future of work, including solutions that fight stigma and increase workplace support related to menopause.

Best Practices for Engaging a Multigenerational Workforce

Employers are grappling with a myriad of workforce-related issues ranging from productivity to attracting and retaining talent, but many may be overlooking some seismic shifts that are reshaping the future of work: longevity, population aging, and the multigenerational workforce.

Brazil Must Fight Antibiotic Resistance

The threat posed by antimicrobial resistance is urgent and spares no country - including Brazil. According to The Lancet, 63 deaths per 100,000 are associated with AMR in Brazil and Paraguay, a rate that exceeds the average for Latin America and the Caribbean. AMR-associated deaths in Brazil are second only to cardiovascular diseases and cancers.